Generating T cell Immunity to Sarcoma by Liposomal Vaccination with Sarcoma Fusion Breakpoints
We have developed a liposomal vaccine that delivers long peptides into the processing/presentation machinery of antigen presenting cells and generates outstanding cytotoxic T cell responses. We propose the use of this vaccine for generating T cell immunity to the breakpoint regions of four sarcoma-derived oncofusion proteins: EWS-ATF1, SYT-SSX, TLS-CHOP, and ASPL-TFE3. Experiments will be conducted to demonstrate that peptides within these breakpoints 1) are processed and presented by human antigen presenting cells, and 2) activate a population of cytotoxic T lymphocytes capable of killing human sarcoma cells. These studies will facilitate rapid clinical translation of four novel sarcoma vaccines.